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Abstract - Vulvar and vaginal atrophy (VVA), is a chronic medical condition experienced by post-
menopausal women, with prevalence estimated ranging from 10% to 50% [1]. VVA is characterized by a 
constellation of symptoms, that may affect daily activities, sexuality, relationships, and quality of life [3]. 
Early recognition and effective treatment of VVA may enhance sexual health and the quality of life of wom-
en and their partners. Some vulvar conditions such as lichen sclerosus are more prevalent in the postmeno-
pausal years. Lichen sclerosus has been suggested as a precursor of  Vulvar squamous cell carcinoma. The 
vulvar exam in post-menopausal women plays an essential role in prevention of cancer because it allows to 
identify women who should undergo vulvar skin biopsy in order to early detect  pre-neoplastic lesions for 
early diagnosis of cancer of the vulva.  
 




Vulvar and vaginal atrophy (VVA), is a chronic medical 
condition experienced by post-menopausal women, with 
prevalence estimated ranging from 10% to 50% [1]. 
VVA, resulting from the loss of estrogen stimulation, is 
characterized by thinning of the epithelial lining of the 
vagina and lower genitourinary tract, by loss of vaginal 
elasticity, by vaginal dryness and by an increase of vagi-
nal Ph [2], determining a significant impact on sexual 
health and quality of life. VVA is characterized by a con-
stellation of symptoms, such as vaginal dryness, burning 
and irritation, lack of lubrication, dyspareunia, dysuria, 
and urinary urgency that may affect daily activities, sexu-
ality, relationships, and quality of life [3]. Unlike hot 
flushes that usually resolve over time, VVA has a chronic 
progressive nature throughout the menopausal transition 
and beyond. The presence and severity of symptoms are 
variable, from mild discomfort to great impairment, de-
pending also on age, time and type of menopause, parity 
and vaginal delivery, frequency of coital activity, ciga-
rette smoking and certain medical conditions [4]. 
The REVIVE survey was an online evaluation of post-
menopausal women in the US. The recently published 
REVIVE (REal Women’s VIews of Treatment Options 
for Menopausal Vaginal ChangEs) survey, offers many 
insights into the impact of VVA symptoms on women’s 
lives. The most commonly reported VVA symptoms 
among post-menopausal women were vaginal dryness 
(55%), dyspareunia (44%), and local irritation (37%) [5].  
While the clinical picture of VVA and other conditions 
subsequent to menopause have been thoroughly de-
scribed, there has been little quantitative research on the 
association of VVA with other disorders, such as the 
structural modifications of the vulvar skin.  
Vulvar  itching is the main symptom of Lichen sclerosus 
 of  the  vulva, a  chronic  dermatologic  condition  char-
acterized  by  pruritus, inflammation  and  tissue  scar-
ring,  most  often affecting  post-menopausal  women. [6]  
Additionally, women  may report  cracking  or  bleeding 
 of  the  vulvar  skin and  perianal  area.   
Patients with lichen sclerosus especially those with 
squamous cell hyperplasia have an increased risk of vul-
var malignancy. The increased risk of developing squa-
mous cell carcinoma is approximately 5 percent in pa-
tients with lichen sclerosus [7]. Accurate diagnosis is es-
sential for effective treatment. The risk of progression to 
malignancy associated with some of these diseases dic-
tates long-term surveillance [8].  
This paper discusses implication of  VVA symptoms on 
women’s lives and stresses value of vulvar exam in early 




II.  METHODOLOGY Our study population included  44 sexually active post-
menopausal women 50 to 75 years old, recruited from 
LILT ambulatory in Avellino, Italy. We administered the 
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Vulvovaginal Symptoms Questionnaire (VSQ), a previ-
ous validated instrument to post-menopausal women.   
The first six questions of the questionnaire  comprise the 
symptom subscale (itching, burning, dryness, 
dyspareunia, urinary frequency, urinary urgency). Wom-
en who answered "Yes" to any of the first six symptom 
questions were considered to have vulvovaginal symp-
toms. 
Eligible participants were all Italian women in post-
menopause, which is defined as the presence of amenor-
rhea for at least 12 months. These women consulted an 
outpatient gynecological service for a routine gynecolog-
ical examination. Among eligible women, only those who 
signed an informed consent were enrolled into the study.  
All women were subjected to a medical interview through 
which demographic information, personal and family 
medical history and comorbidities were recorded. Subjec-
tive symptoms considered were: vaginal dryness, itching, 
burning, dysuria and dyspareunia.  
Objective signs taken into consideration were: thinning of 
vaginal rugae, bleeding at slightest touch, bleeding at in-
tense touch and presence of petechiae. 
 
III.  RESULTS 
Post-menopausal women included in Our study reported 
at least one vulvovaginal symptom. The most common 
symptom reported is dryness 88.63% (n/N= 39/44), 
whereas the symptoms recorded less frequently are uri-
nary frequency 38.63% (n/N= 17/44) and urinary urgency 
34.09% (n/N=15/44). Vulvovaginal symptoms have im-
portant repercussions on the sexual sphere, in fact the 
symptom of dyspareunia was recorded in 54.54% (n/N= 
24/44) of sexually active post-menopausal women. Size-
able proportions of women with vulvovaginal symptoms 
report itching in 52.27% (n/N=23/44) and burning 




Graphic 1:  Incidence of VVA symptoms 
  
Objective examination of the external genitalia allowed to 
record several alterations of the vulvar skin. Alterations 
of the vulvovaginal mucosa were classified into five cat-
egories: normal mucosa, thinned mucosa, bleeding at the 
slightest touch, bleeding at intense touch and presence of 
petechiae. (Graphic 2: Alterations of vulvovaginal muco-
sa. Comparing two groups: women with no itching and 
itching)  
In the subgroup of post-menopausal women presenting 
itching 52.27% (n/N=23/44), only 26,08% (n/N=6/23)  of 
sexually active post-menopausal women have normal 
mucosa,  whereas  73,91% (n/N= 17/23) show alterations 
of the vulvar skin. (Graphic 3: Alterations of vulvovagi-
nal mucosa in the subgroup of women presenting itching) 
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Graphic 3: Alterations of vulvovaginal mucosa in the subgroup of women presenting itching 
 
 
The results of the evaluation of the external genitalia 
show the presence of thinned mucosa in 47,05% (n/N= 
8/17), bleeding at slightest touch in 11,75% (n/N= 2/17), 
bleeding at intensive touch in 29,41% (n/N= 5/17) and 
presence of petechiae in 11,75% (n/N= 2/17). (Graphic 4: 
Pathological aspects of vulvovaginal mucosa in the sub-
group of women presenting itching)
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Graphic 4: Pathological aspects of vulvovaginal mucosa in the subgroup of women presenting itching 
 
 
IV.  DISCUSSION 
Pathogenesis of  VVA symptoms is reflected in the re-
duction in the level of estrogenic hormones, typical phe-
nomenon which occurs in the period of menopause.  
Estrogen receptors, alpha and beta, are expressed 
throughout the squamous epithelium, connective tissue 
and smooth muscle of the vulva, vagina, urethra, and 
bladder trigone and are critical for mediating numerous 
biochemical and physiologic functions during a woman’s 
reproductive years [9]. With loss of estrogen stimulation, 
profound changes occur within the vulvovaginal and uro-
genital mucosa. In the dermal layer, collagen fibers fuse 
and undergo hyalinization, whereas the elastin fibers 
fragment. The result of these changes is an overall loss of 
mucosal elasticity and the vaginal epithelium thinning 
[10]. 
Estrogen-induced parakeratosis of the vulvar squamous 
epithelium progressively decreases after menopause and 
is rarely seen in older women. The vagina loses its rugae, 
and there is a shortening and narrowing of the vagina. 
The mucosa of the vagina, introitus, and labia minora be-
come thin and pale. Surrounding vascularity, highly es-
trogen dependent, also decreases. [11]   
Vulvar disease in the post-menopausal age group is rela-
tively common. Some vulvar conditions such as lichen 
sclerosus are more prevalent in the post-menopausal 
years. Often more than one condition is present at the 
same time [8]. Lichen  sclerosus  of  the  vulva  is  a 
chronic  dermatologic  condition  characterized  by  pruri-
tus, inflammation  and  tissue  scarring [6]. The  distribu-
tion of  skin  changes  may  involve  the  perianal  skin, 
and  scarring  can  cause  fusion  of  the  labia  minora to 
 the  labia  majora and flattening of the clitoral hood, 
 which  may  result  in  immobility [12].  
Physical  examination  is  important  for  differentiating 
 lichen  sclerosus  from  other  causes  of vulvar  pruritus, 
 such  as  lichen  planus,  lichen  simplex  chronicus, 
 atrophic  vaginitis,  irritant  contact dermatitis,  eczema, 
 psoriasis,  vulvovaginal  candidiasis  and  skin  cancers 
 (e.g.,  vulvar  intraepithelial neoplasia  and  extra-
mammary  Paget  disease) [13].   
Patients with lichen sclerosus, especially those with 
squamous cell hyperplasia, have an increased risk of vul-
var malignancy and should be monitored accordingly. 
The increased risk of developing squamous cell carcino-
ma is approximately 5 percent in patients with lichen 
sclerosus. [7].  
Recognition and treatment of these vulvar conditions is 
important for symptom relief, sexual function, prevention 
of progressive vulvar scarring, and to provide surveil-
lance for associated vulvar cancer [14].  
Vulvar cancer is a relatively rare gynecologic malignancy 
with an annual incidence in developed countries of ap-
proximately 2 per 100,000 women. Vulvar squamous cell 
carcinoma (VSCC) has two etiological pathways: a high 
risk human papillomavirus (HPV)-dependent route, 
which has usual vulvar intraepithelial neoplasia (uVIN) 
as a precursor lesion, and an HPV-independent route, 
which is associated with differentiated VIN (dVIN), li-
chen sclerosus, and genetic alterations, such as TP53 mu-
tations [15].  
Most VSCCs originate in intraepithelial lesions, named 
vulvar intraepithelial neoplasia (VIN), that precede the 
development of VSCC by a variable period of time. Epi-
thelial disorders are found adjacent to VSCC in 50–70% 
of patients. Most of these intraepithelial changes appear 
to have some degree of dysplasia [16]. 
Lichen sclerosus (LS) has also been suggested as a pre-
cursor of HPV-independent VSCC, but the mechanism of 
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carcinogenic progression from LS has not been fully de-
lineated.  The association between the two entities has 
been established mainly because the majority of vulvar 
cancers will have lichen sclerosus, squamous cell hyper-
plasia or differentiated VIN in the adjacent epidermis 
[17] and because some longitudinal cohort studies have 
shown that women with LS have a significantly higher 
risk of developing VSCC.[18] 
It is clear the value of the vulvar exam to identify the 
presence of skin changes associated with the presence of 
a preneoplastic lesions.  
Cancer Research UK publishes the symptoms of vulvar 
cancer [19] 
  a lasting itch 
  pain or soreness 
  thickened, raised, red, white or dark patches on 
the skin of the vulva 
  an open sore or growth visible on the skin 
  burning pain when you pass urine 
  vaginal discharge or bleeding 
  a mole on the vulva that changes shape or col-
our 
 a lump or swelling in the vulva 
The presence of these alterations should be an alarm bell 
and must lead the gynecologist to perform a vulvar skin 
biopsy. Vulvar biopsy is the only method to get a histo-
pathological diagnosis when there is a vulvar lesion of 
uncertain significance, or in the presence of persisting 
symptoms, such as vulvar irritation or itching [20].  
  
V.  CONCLUSION 
VVA symptoms negatively affect the quality of life of 
menopausal women, complicating interpersonal relation-
ships and married life. Early recognition and effective 
treatment of VVA may enhance sexual health and the 
quality of life of women and their partners.  
Lichen sclerosus has been suggested as a precursor of 
HPV-independent VSCC. The etiology of lichen scle-
rosus is multifactorial; therefore, patient education, be-
havior modification, and regular follow-up with an expe-
rienced clinician are essential to ensure effective control 
of patient symptoms and management of the skin condi-
tion. The vulvar exam in post-menopausal women plays 
an essential role in the early detection of pre-neoplastic 
lesions. In presence of injuries such as itch, pain, raised 
patches and bleeding, the gynecologist must start a thera-
peutic treatment. If during the follow-up of skin lesions 
there is a lack of response to treatment or a progression of 
lesions, the gynecologist must proceed with the execution 
of a biopsy of the vulvar skin. The recognition of vulvar 
lesions is important for the prevention and early diagnosis 
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